Sequential Nephron Blockade in Acute Heart Failure

Status Recruiting

Clinical Trial Summary

Background - Volume overload is an important clinical target in acute heart failure management (AHF), typically addressed using loop diuretics. An important and challenging subset of heart failure patients exhibit fluid overload despite significant doses of loop diuretics. One approach to overcome loop diuretic resistance is the addition of a thiazide-type diuretic to produce diuretic synergy via "sequential nephron blockade". Although potentially able to induce diuresis in patients otherwise resistant to high doses of loop diuretics, this strategy has not been subjected to large-scale clinical trials to establish safety and clinical efficacy.

Methods - Our trial is a multicentric, double blind, randomized clinical study, aiming to recruit 310 patients with AHF and clinically evident volume overload. Study participants are randomized to receive a standard diuretic therapy (intravenous loop diuretics as recommended by current guidelines plus placebo) or SNB therapy (loop diuretics plus oral metolazone at the dose of 5/10 mg once daily) on top of standard medical therapy. Mineralocorticoid antagonists will be used in association with the two regimens according to blood potassium level and kidney function at the discretion of the treating physician. The primary endpoint is defined as the change in the serum creatinine level and the change in weight, considered both as a bivariate response and with their single components, between the time of randomization and 72 hours after randomization. Secondary endpoints include global well-being and dyspnoea assessed by a visual-analogue scale, changes in body weight and net fluid loss, proportion of patients free from congestion, treatment failure, changes in biomarker levels and the composite of death, rehospitalization, or an emergency room visit within 60 days, as well as the composite of total number of days hospitalized or death during the 60 days after randomization.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04163588
Study type	Interventional
Source	Policlinico Casilino ASL RMB
Contact	Gennaro Cice, MD
Phone	0039330915294
Email	gennarocice@hotmail.com
Status	Recruiting
Phase	Phase 3
Start date	October 1, 2019
Completion date	December 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02151383` - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure	Phase 2
Completed	`NCT02135835` - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure	Phase 4
Recruiting	`NCT05556044` - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction	Phase 3
Recruiting	`NCT04363697` - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)	Phase 4
Completed	`NCT02122640` - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department	N/A
Completed	`NCT01193998` - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department	N/A
Not yet recruiting	`NCT01211886` - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)	N/A
Not yet recruiting	`NCT06465498` - Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography	N/A
Recruiting	`NCT05276219` - Optimized Treatment of Pulmonary Edema or Congestion	Phase 4
Recruiting	`NCT05392764` - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	Phase 3
Recruiting	`NCT03157219` - Manipal Heart Failure Registry (MHFR)	N/A
Completed	`NCT06024889` - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.	Phase 1/Phase 2
Terminated	`NCT04174794` - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting	`NCT05972746` - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure	N/A
Enrolling by invitation	`NCT02258984` - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial	N/A
Completed	`NCT02141607` - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed	`NCT01870778` - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF	Phase 3
Recruiting	`NCT05986773` - Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance	Phase 4
Recruiting	`NCT04329234` - Korean Heart Failure Registry III
Recruiting	`NCT03717636` - Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.